Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Archimedes Pharma UK

1996 FOUNDED
M&A STATUS
21-30 EMPLOYEES
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of pharmaceutical products. The company offers Gliadel, a treatment for high-grade gliomas; Zomorph for cancer pain; Nozinan, an anti-emetic for nausea and vomiting in advanced cancer patients; and Pabrinex, a high-potency formulation of vitamins B and C for chronic alcoholics. It operates in the United Kingdom, France, and Germany.

Formerly Known As
Link Holdings
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Other Healthcare Services
Other Industries
Pharmaceuticals
Primary Office
  • 250 South Oak Way
  • Green Park
  • Reading RG2 6UG
  • England

+44 0118 000 0000

Archimedes Pharma UK Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Archimedes Pharma UK‘s full profile, request access.

Request full access to PitchBook

Archimedes Pharma UK Board Members (1)

Name Representing Role Since Contact
Info
000 000 Self Board Member 000 0000